Patents Assigned to GPC-Biotech Inc.
-
Patent number: 7605175Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.Type: GrantFiled: April 7, 2004Date of Patent: October 20, 2009Assignees: GPC Biotech AG, GPC Biotech, Inc.Inventors: Frank Becker, Nicholas Bockovich, Jon H. Come, Arthur F. Kluge, Krishna K. Murthi, Chris Oalmann, Siya Ram, Zhongguo Wang
-
Publication number: 20090209530Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.Type: ApplicationFiled: December 21, 2004Publication date: August 20, 2009Applicant: GPC Biotech, Inc.Inventors: Nicholas Bockovich, Arthur F. Kluge, Chris Oalmann, Krishna K. Murthi, Siya Ram, Zhongguo Wang, Jianxing Huang
-
Patent number: 7566455Abstract: The present invention relates to the discovery in eukaryotic cells, particularly human cells, of novel protein-protein interactions between certain cellular proteins, referred to herein as “E6AP-binding proteins” or “E6AP-BPs”, and the cellular protein E6AP, the latter of which is a component of a ubiquitin-ligase (E3) enzyme. The association of E6AP and the subject E6AP-binding proteins implicates the E6AP-binding proteins in a number of basic cellular functions, such as regulation of gene expression, regulation of the cell-cycle, modification of cell surface receptors, biogenesis of ribosomes, and DNA repair. One of the E6AP-binding proteins shares certain homology with the papillomavirus E6 protein, which also binds E6AP.Type: GrantFiled: June 7, 1995Date of Patent: July 28, 2009Assignee: GPC Biotech, Inc.Inventors: Peggy L. Beer-Romero, Giulio Draetta, Mark Rolfe
-
Publication number: 20080146555Abstract: The invention pertains to inhibitors of various kinases (e.g. S/T kinases, Tyr kinases, etc.), which inhibitors are previously known as cyclin dependent kinase inhibitors (CDKs). As described herein, the inhibitors of this invention are capable of inhibiting various wild-type and mutant form kinases, including drug resistant forms of mutant kinases. Thus the subject kinase inhibitors are useful in treating a wide range of diseases/conditions associated with abnormal functions/excessive activities of the target kinases, including mutant kinases. The invention further provides methods for treating cancers, tumors and patients which are resistant or refractory to other therapeutic agents. Pharmaceutical compositions and packaged pharmaceuticals with instructions of these inhibitors, and methods of using these inhibitors are also provided.Type: ApplicationFiled: June 17, 2005Publication date: June 19, 2008Applicant: GPC Biotech, IncInventors: Maureen G. Caligiuri, Nikolai A. Kley, Krishna K. Murthi
-
Patent number: 7230101Abstract: The present invention relates to novel compositions of methotrexate-containing heterodimeric probe molecules, also known as chemical inducers of dimerization (CID), useful in three-hybrid assays. The invention further relates to synthesis of said compositions and their intermediates. Another aspect of the invention is a method for using the heterodimeric probe molecules described herein in drug screens to identify potential protein targets to a given ligand, optimize protein-ligand interactions, or identify potential ligands for a given protein target.Type: GrantFiled: August 28, 2003Date of Patent: June 12, 2007Assignee: GPC Biotech, Inc.Inventors: Krishna K. Murthi, Chase C. Smith
-
Patent number: 7135550Abstract: The invention provides compositions and methods for isolating ligand binding polypeptides for a user-specified ligand, and for isolating small molecule ligands for a user-specified target polypeptide using an improved class of hybrid ligand compounds.Type: GrantFiled: September 3, 2002Date of Patent: November 14, 2006Assignees: GPC Biotech Inc., GPC Biotech AGInventors: Jon H. Come, Frank Becker, Nikolai A. Kley, Christoph Reichel
-
Publication number: 20050090471Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.Type: ApplicationFiled: October 15, 2002Publication date: April 28, 2005Applicants: GPC Biotech, Inc, GPC Biotech AGInventors: Nicholas Bockovich, Arthur Kluge, Siya Ram, Zhongguo Wang, Chris Oalmann, Krishna Murthi, Frank Becker
-
Publication number: 20040266853Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.Type: ApplicationFiled: April 6, 2004Publication date: December 30, 2004Applicant: GPC Biotech, Inc.Inventors: Nicholas Bockovich, Arthur Kluge, Chris Oalmann, Krishna K. Murthi, Siya Ram, Zhongguo Wang, Jianxing Huang
-
Publication number: 20040266854Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.Type: ApplicationFiled: April 7, 2004Publication date: December 30, 2004Applicants: GPC Biotech, Inc., GPC Biotech AGInventors: Frank Becker, Nicholas Bockovich, Jon H. Come, Arthur Kluge, Krishna K. Murthi, Chris Oalmann, Siya Ram, Zhongguo Wang
-
Patent number: 6753329Abstract: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.Type: GrantFiled: December 17, 2002Date of Patent: June 22, 2004Assignees: GPC Biotech Inc., GPC Biotech AGInventors: Nicholas Bockovich, Arthur Kluge, Chris Oalmann, Krishna K. Murthi, Frank Becker
-
Patent number: 6747128Abstract: The present invention relates to the isolation of a new class of ubiquitin ligases involved in protein degradation in vertebrate organisms, such as protein degradation of cell cycle regulatory proteins. Accordingly, the invention provides nucleic acids and the proteins encoded by said nucleic acids which play a role in the ubiquitinylation and subsequent degradation of substrate proteins and in regulating cell proliferation, cell differentiation, and cell survival.Type: GrantFiled: August 20, 1997Date of Patent: June 8, 2004Assignee: GPC Biotech, Inc.Inventors: Maureen Caligiuri, Mark Rolfe
-
Patent number: 6727082Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis. Another aspect of the present invention relates to novel Candida genes and gene products.Type: GrantFiled: March 13, 1998Date of Patent: April 27, 2004Assignee: GPC Biotech Inc.Inventors: Vivian Berlin, Veronique Damagnez, Susan E. Smith
-
Patent number: 6696280Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis. Another aspect of the present invention relates to novel Candida genes and gene products.Type: GrantFiled: August 31, 2001Date of Patent: February 24, 2004Assignee: GPC Biotech, Inc.Inventors: Vivian Berlin, Veronique Damagnez, Susan E. Smith
-
Patent number: 6521602Abstract: Disclosed is a nucleic acid composition consisting essentially of a first nucleic acid sequence encoding a chimeric CDKi protein and a second nudeic acid sequence encoding an adenovirus E4 protein, wherein the first and second nucleic acid sequences are operably linked to at least one regulatory sequence.Type: GrantFiled: March 1, 2000Date of Patent: February 18, 2003Assignees: GPC Biotech Inc., Cell Genesys, Inc.Inventors: Salil Patel, James McArthur, Jeno Gyuris, Michael J. Mendez, Mitchell H. Finer
-
Patent number: 6495526Abstract: The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced.Type: GrantFiled: July 29, 1997Date of Patent: December 17, 2002Assignee: GPC Biotech, Inc.Inventors: Jeno Gyuris, Lou Lamphere, David H. Beach
-
Patent number: 6455281Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis. Another aspect of the present invention relates to novel Candida genes and gene products.Type: GrantFiled: December 20, 1996Date of Patent: September 24, 2002Assignee: GPC Biotech Inc.Inventors: Vivian Berlin, Veronique Damagnez, Susan E. Smith
-
Patent number: 6423519Abstract: The present invention relates to compositions and methods for inhibiting fungal growth. In particular, the present invention relates to methods for use as anti-fungal agents of inhibitors, and compositions thereof, of fungal GGPTase. The inhibitors of fungal GGPTase may be peptides, peptidomimetics, or non-peptides.Type: GrantFiled: October 15, 1998Date of Patent: July 23, 2002Assignee: GPC Biotech Inc.Inventors: Gustave Bergnes, Vivian Berlin, Jon Come, Arthur Kluge, Krishna Murthi, Kollol Pal
-
Patent number: 6420345Abstract: Disclosed are methods for inhibiting angiogenesis using cyclin dependent kinase inhibitors (CDKi) and fusion proteins thereof, recombinant viruses comprising transgenes and nucleic acid sequences encoding the same, and liposomes carrying the same as angiogenesis-inhibiting reagents.Type: GrantFiled: December 9, 1999Date of Patent: July 16, 2002Assignees: Cell Genesys, Inc., GPC Biotech Inc.Inventors: Salil Patel, James McArthur, Jeno Gyuris
-
Patent number: 6420110Abstract: One aspect of the present invention is the synthesis of a binary method that combines variegated peptide display libraries, e.g., in a “display mode”, with soluble secreted peptide libraries, e.g., in a “secretion mode”, to yield a method for the efficient isolation of peptides having a desired biological activity.Type: GrantFiled: October 19, 1998Date of Patent: July 16, 2002Assignee: GPC Biotech, Inc.Inventors: Jeno Gyuris, Aaron J. Morris
-
Patent number: 6413943Abstract: Disclosed are methods for using &Dgr;E1/&Dgr;E4 recombinant adenoviruses encoding cyclin dependent kinase inhibitors (CDKi's) as reagents for inhibiting smooth muscle cell proliferation. Also disclosed are recombinant lentiviruses encoding cyclin dependent kinase inhibitors (CDKi's).Type: GrantFiled: December 9, 1999Date of Patent: July 2, 2002Assignees: Cell Genesys, Inc., GPC Biotech Inc.Inventors: James McArthur, Mitchell H. Finer, Jeno Gyuris